ESPRHealthcare · Drug Manufacturers - Specialty & GenericESPR Stock Forecast: Esperion Therapeutics, Inc. Price Predictions for 2026-2027
ESPR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Esperion Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
We don’t hold a current model rank for this company.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ESPR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ESPR, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 May 2026 | Needham | Downgrade | Hold | — |
| 1 May 2026 | HC Wainwright & Co. | Downgrade | Neutral | $3.16 |
| 13 Mar 2026 | Citizens | Maintains | Market Outperform | — |
| 3 Mar 2026 | Needham | Maintains | Buy | — |
| 25 Nov 2025 | Piper Sandler | Initiates | Overweight | — |
| 19 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 May 2025 | Needham | Maintains | Buy | — |
| 25 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Apr 2025 | Needham | Reiterates | Buy | — |
| 17 Apr 2025 | Goldman Sachs | Maintains | Neutral | — |
| 8 Apr 2025 | Needham | Reiterates | Buy | — |
| 20 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 4 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 23 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Jan 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ESPR appears on the weeks it earns a place.
ESPR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Esperion Therapeutics, Inc. (ESPR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −28.9×
- Price / sales
- 2.0×
- Price / book
- −2.6×
- EV / EBITDA
- 15.9×
Cheaper than 97% of US stocks
Cheaper than 54% of US stocks
Cheaper than 96% of US stocks
Cheaper than 22% of US stocks
- Revenue growth (YoY)
- 23.2%
- Earnings growth (YoY)
- 23.2%
- Gross margin
- 56.8%
- Operating margin
- −8.2%
- Net margin
- −1.8%
Higher than 73% of US stocks
Higher than 62% of US stocks
Higher than 70% of US stocks
Higher than 25% of US stocks
Higher than 28% of US stocks
- Return on equity
- 7.5%
- Return on assets
- 12.0%
- Dividend yield
- —
Higher than 58% of US stocks
Higher than 95% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Esperion Therapeutics, Inc. (ESPR) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Esperion Therapeutics, Inc. has a market value of $819.5M and an enterprise value of $1.2B.
Revenue in the twelve months to 31 Mar 2026: $418.2M. The latest quarter grew 23.2% year on year.
Net income over the same four quarters: −$7.4M, a −1.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.06.
Free cash flow in the twelve months to 31 Mar 2026: −$18.4M, after $189K of capital spending.
Trailing P/E: −28.9×; forward P/E: 12.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Esperion Therapeutics, Inc. employs 294 people — $1.4M of revenue per employee.
Data provided by Twelve Data
ESPR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| ESPREsperion Therapeutics, Inc. | $819.5M | — |
| LLYEli Lilly & Co.* | $1.2T | 91 |
| JNJJohnson & Johnson* | $650.8B | 92 |
| ABBVAbbVie, Inc.* | $468.1B | 96 |
| MRKMerck & Co., Inc.* | $378.6B | 83 |
| UNHUnitedHealth Group, Inc.* | $353.4B | 75 |
| AMGNAmgen, Inc.* | $236.8B | 92 |
* Nearest Healthcare names by size — few drug manufacturers - specialty & generic companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Esperion Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ESPR stock
What is the ESPR stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Esperion Therapeutics, Inc. have a median 12-month price target of $3.16, with estimates ranging from $3.16 to $3.28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ESPR stock a buy right now?
Of the 5 analysts covering Esperion Therapeutics, Inc., 0 rate it a Buy, 5 a Hold and 0 a Sell. None of this is personal advice — it does not consider your circumstances.
Will ESPR stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies from the last close. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ESPR stock forecast for 2030?
No analyst covering Esperion Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ESPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.16 to $3.28 over the next 12 months.
What does Esperion Therapeutics, Inc. do?
Esperion Therapeutics Inc. is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines designed for patients with elevated low-density lipoprotein cholesterol.
About Esperion Therapeutics, Inc.
Esperion Therapeutics Inc. is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines designed for patients with elevated low-density lipoprotein cholesterol. The company's primary marketed products are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which serve patients with primary hyperlipidemia, including those with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional LDL-C lowering. These therapies address patients who are statin-intolerant or require supplementary cholesterol management beyond traditional treatments. Esperion has expanded its global reach through partnerships, with its bempedoic acid products now available in markets including Japan and Canada. The company operates in the cardiovascular health segment, focusing on closing treatment gaps in dyslipidemia management. Founded in 1998 and headquartered in Ann Arbor, Michigan, Esperion operates as a commercial-stage biopharmaceutical company dedicated to advancing treatment options for patients with elevated cholesterol and related cardiovascular risk factors.
CEO Mr. Sheldon L. Koenig M.B.A. · 294 employees · United States · https://www.esperion.com